Peking University Institute of Cardiovascular Sciences
Xunde Xian
Dr. Xunde Xian, Principal Investigator
EDUCATION
• Ph.D. in Physiology | Peking University | 09/2003-07/2008
• B.S. in Pharmacology | Peking University | 09/1999-07/2003
WORK EXPERIENCE
Assistant professor | Peking University Institute of Cardiovascular Sciences | 08/2019-present
Assistant professor | Molecular Genetics at UTSW Medical Center | 09/2015 - 08/2019
• Currently involved in the research model implementation (project planning, execution, and
monitoring; data collecting and analyzing; paper writing; collaborating with PIs for grant writing)
• Training M.D./Ph.D. students in the lab (project designing and conducting; data analysis; literature
reading)
• Train postdoc fellows in the lab (project designing and conducting; data analysis; literature
reading)
Instructor | Department of Molecular Genetics at UTSW Medical Center | 07/2012 – 08/2015
• Currently involved in the research model implementation (project planning, execution, and
monitoring; data collecting and analyzing; paper writing; collaborating with PIs for grant writing)
• Train M.D./Ph.D. students in the lab (project designing and conducting; data analysis; literature
reading)
Postdoc fellow | Department of Molecular Genetics at UTSW Medical Center | 11/2008 – 06/2012
• Integrate postdoc projects (project planning and conducting; data analyzing; and paper writing)
• Train summer students in the lab (experiment design and execution; data analysis)
Visiting fellow | Centre for Molecular Medicine and Therapeutics at UBC | 07/2007 – 10/2007
• Study multiple functions of lipoprotein lipase in Atherosclerosis and brain
Visiting fellow | Diagonistics at Agilent Technologies and Pathology Department of Stanford | 06/2006
•Developing the application of Lipo-Chip in the patients with metabolic syndrome
Personal Profile
Xunde Xian, Researcher at the Peking University Cardiovascular Research Institute, Ph.D. supervisor, Principal Investigator of the State Key Laboratory of Vascular Homeostasis and Remodeling, Director of the Laboratory for Lipid Metabolism Disorders and Metabolic Cardiovascular Diseases, recipient of the National High-Level Overseas Talent Youth Program, and Boya Young Scholar at Peking University.
The main focus is on research in lipid metabolism regulation and metabolic cardiovascular diseases. A series of genetically engineered hamster models for lipid metabolism disorders with independent intellectual property rights in China have been established. Research findings have been published in internationally renowned journals such as European Heart Journal, Journal of Hepatology, Circulation Research, ATVB, PNAS, eLife, Science Signaling, EBioMedicine and Metabolism.
Awards include the Outstanding Young Talent Award from the Chinese Association for Laboratory Animal Sciences in 2020, the First Prize of the Beijing Medical Association Science and Technology Award in 2022, and the Second Prize of the Beijing Association for Science and Technology Natural Science and Technology Award. A total of 11 international and national patents have been granted.
Currently serving as an executive member of the Arteriosclerosis Committee of the Chinese Society of Pathophysiology, Vice Chair of the Chinese Branch of the International Atherosclerosis Society, and on the editorial boards of Atherosclerosis and Scientific Reports. Additionally, an invited reviewer for journals such as Nature Cell Biology, Nature Communications, Journal of Clinical Investigation, and PNAS.
Selected First/Corresponding Author Publications in the Last Five Years
1. Yitong Xu, Jingxuan Chen, Yiran Liu, Ge Zhang, Guolin Miao, Jingdong Wu, Kaikai Lu, Yinqi Zhao, Wenxi Zhang, Liwen Zheng, Lianxin Zhang, Jinxuan Chen, Zihao Zhou, Yufei Han, Pingping Lai, Jiabao Guo, Donghui Wu, Si Mei, Ling Zhang, Yang Zhao, Wei Huang, Yuhui Wang, Junnan Tang, Dongyu Zhao, Xunde Xian #(Corresponding author). The macrophage-derived motor protein KIF13B enhances MERTK-mediated efferocytosis and prevents atherosclerosis in mice. European Heart Journal , 2025. doi:10.1093/eurheartj/ehaf523
2. Kaikai Lu, Yitong Xu, Lei He, Yinqi Zhao, Xunde Xian #(Corresponding author). Revisiting the Role of CBL in Liver Fibrosis: Unveiling the Antifibrotic Potential of CBLB inhibitor NX-1607. J Hepatol. 2025 Mar 25:S0168-8278(25)00211-9. doi: 10.1016/j.jhep.2025.03.023. Epub ahead of print. PMID: 40139509.
3. Pingping Lai, Guolin Miao, Yinqi Zhao, Yufei Han, Yanwei Li, Yiran Liu, Jiabao Guo, Wenxi Zhang, Xin Guo，Yitong Xu，Lianxin Zhang，Gonglie Chen, Zihao Zhou, Si Mei, Jingxuan Chen, Jinxuan Chen，Luzheng Xu, Chong Zhang, Yang Ding，Xiaoguang Dou, Shengmei Wen, Sin Man Lam, Guanghou Shui，Yuhui Wang，Wei Huang, Dongyu Zhao，Xunde Xian #(Corresponding author). SR-A3 suppresses AKT activation to protect against MAFLD by inhibiting XIAP-mediated PTEN degradation. Nature communications. 2025. doi:10.1038/s41467-025-57585-0.
4. GuoLin Miao, WenXi Zhang, YiTong Xu, YiRan Liu, PingPing Lai, JiaBao Guo, GongLie Chen, JingXuan Chen, ZiHao Zhou, YanWei Li, Chong Zhang, Yang Ding, LianXin Zhang, YuFei Han, JinXuan Chen, JingDong Wu, YinQi Zhao, Si Mei, Yang Zhao, YuanWu Ma, Ling Zhang, Wei Huang, DongYu Zhao, ErDan Dong, YuHui Wang and Xunde Xian #(Corresponding author). Motor protein KIF13B orchestrates hepatic metabolism to prevent metabolic dysfunction‑associated fatty liver disease. Mil Med Res . 2025. doi: 10.1186/s40779-025-00594-3.
5. JingXuan Chen, YiTong Xu, Huahui Yu, Yiran Liu, GuoLin Miao, YuFei Han, Liwen Zheng, Zeyu Cai, ZiHao Zhou, Jinxuan Chen, Sijing Shi, Pingping Lai, Wenxi Zhang, Lianxin Zhang, Si Mei, Yinqi Zhao, Ling Zhang, Wei Huang, Yuhui Wang, Dongyu Zhao, Wei Kong, Yanwen Qin, Erdan Dong, Xunde Xian #(Corresponding author). Macrophage-derived KIF13B interacts with USP9X to attenuate abdominal aortic aneurysm development by potentiating TFEB stability. Theranostics. 2025 Aug 16;15(17):9114-9130. doi: 10.7150/thno.118958. PMID: 40963913; PMCID: PMC12439347.
6. Zhidan Zhang, Meijie Chen, Yitong Xu, Zhihua Wang, Zhenghong Liu, Chenyang He, Fanshun Zhang, Xiaojun Feng, Xiayun Ni, Yuanli Chen, Jixia Wang, Xinmiao Liang, Zhifu Xie, Jingya Li, Maciej Banach, Jaroslav Pelisek, Yuqing Huo, Yunhui Hu, Paul C Evans, Li Wang, Xiao-Yu Tian, Jianbo Xiao, Yuhua Shang, Yijun Zheng , Xunde Xian #(Corresponding author), Jianping Weng#，Suowen Xu#，Theranostics. 2025 Mar 18;15(10):4325-4344. (IF="12.4)
7. Jiabao Guo, Guolin Miao, Wenxi Zhang, Haozhe Shi, Pingping Lai, Yitong Xu, Lianxin Zhang, Gonglie Chen, Yufei Han, Ying Zhao, George Liu, Ling Zhang, Yuhui Wang, Wei Huang, Xunde Xian #(Corresponding author). Depletion of ApoA5 aggravates spontaneous and diet-induced nonalcoholic fatty liver disease by reducing hepatic NR1D1 in hamsters. Theranostics . 2024. doi:10.7150/thno.91084.
8. Guolin Miao; Jiabao Guo; Pingping Lai; Wenxi Zhang; Yitong Xu; Jingxuan Chen; Lianxin Zhang; Zihao Zhou; Yufei Han; Gonglie Chen; Jinxuan Chen; Yijun Tao; Lemin Zheng; Ling Zhang; Wei Huang; Yuhui Wang; Xunde Xian #(Corresponding author). Remodeling Intestinal Microbiota Alleviates Severe Combined Hyperlipidemia-Induced Non-Alcoholic Steatohepatitis and Atherosclerosis in LDLR-/- Hamsters, Research . 2024. doi: 10.34133/research.0363.
9. Wenxi Zhang, Jiabao Guo, Guolin Miao, Jingxuan Chen, Yitong Xu, Pingping Lai, Lianxin Zhang, Yufei Han, Sin Man Lam, Guanghou Shui, Yuhui Wang, Wei Huang, Xunde Xian #(Corresponding author). Fat-1 ameliorates MAFLD and atherosclerosis through promoting the nuclear localization of PPARα in hamsters. Research. 2025. doi:10.34133/research.0577.
10. Meijie Chen, Yitong Xu, Lu Sun, Zhi-hua Wang, Peter J. Little, Li Wang, Xunde Xian #(Corresponding author), Jian-ping Weng, Suo-wen Xu. A Novel Mouse Model of Familial Combined Hyperlipidemia and Atherosclerosis. Acta Pharmacologica Sinica 2024. doi:10.1038/s41401-024-01241-8.
11. Yitong Xu, Wenxi Zhang, Jiabao Guo, Jinxuan Chen, Guolin Miao, Lianxin Zhang, Yufei Han, Jingxuan Chen, Ying Zhao, Xunde Xian #(Corresponding author). ApoL1 risk allele accelerates high-fat diet-induced atherosclerosis in LDLR−/− hamsters. Genes & Diseases. 2024. doi: 10.1016/j.gendis.2024.101379.
12. Xiao Lin; Wei Zhang; Chun Yang; Ping Ma; Kunxiang He; Gonglie Chen; Yijun Tao; Haizhao Yan; Zhao Yang; Ling Zhang; Jianglin Fan; Qinghua Cui; Wei Huang; George Liu; Xunde Xian #(Corresponding author); Yuhui Wang#. Depleting LCAT Aggravates Atherosclerosis in LDLR-deficient Hamster with Reduced LDL-Cholesterol Level. J Adv Res . 2023. doi: 10.1016/j.jare.2023.10.016.
13. Chenxi Liang; Xiaowei Wang; Kenan Peng; PingPing Lai; Ziwei Liu; Jiaao Ma; Xin Chen; Gang Liu; Mingqi Zheng; Yuhui Wang; Hongyuan Yang; George Liu; Xunde Xian #(Corresponding author); Mingming Gao ; Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia, Oxid Med Cell Longev. 2022. doi:10.1155/2022/1889632.
14. Haozhe Shi; Jiabao Guo; Qiongyang Yu; Xinlin Hou; Lili Liu; Mingming Gao; Lili Wei; Ling Zhang; Wei Huang; Yuhui Wang; George Liu; Peter Tontonoz; Xunde Xian #(Corresponding author). CRISPR/CAS9 based blockade of IL-10 signaling impairs lipid and tissue homeostasis to accelerate atherosclerosis. Front Immunol . 2022. doi: 10.3389/fimmu.2022.999470.
15. Pohlkamp T*, Xunde Xian*(Co-authors), Wong C*, Durakoglugil M, Werthmann C, Saido, Evers B, White C, Connor J, Hammer R, Herz J. NHECo-authors6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque Load. eLife. 2021.
16. Guo M, Ma S, Xu Y, Huang W, Gao M, Wu X, Dong X, Wang Y, Liu G, Xunde Xian #(Corresponding author). Correction of Familial LCAT Deficiency by AAV-hLCAT Prevents Renal Injury and Atherosclerosis in Hamsters-Brief Report. Arterioscler Thromb Vasc Biol. 2021. Jul;41(7):2141-2148.
17. Guo M, Liu Z, Xu Y, Ma P, Huang W, Gao M, Wang Y, Liu G, Xunde Xian #(Corresponding author). Spontaneous Atherosclerosis in Aged LCAT-Deficient Hamsters With Enhanced Oxidative Stress. Arterioscler Thromb Vasc Biol. 2020 Dec 40(12):2829-2836.
18. Guo M, Xu Y, Dong Z, Zhou Z, Cong NX, Gao M, Huang W, Wang Y, Liu G, Xunde Xian #(Corresponding author). Inactivation of Apoc3 by CRISPR/Cas9 Protects Against Atherosclerosis in Hamsters. Circ Res. 2020 Sep 21. doi: 10.1161/CIRCRESAHA.120.317686.
19. Gao M, Yang C, Wang X, Guo M, Yang L, Gao S, Zhang X, Ruan G, Li X, Tian W, Lu G, Dong X, Ma S, Li W, Wang Y, Zhu H, He J, Yang H, Liu G#, Xunde Xian #(Corresponding author). ApoC2 Deficiency Elicits Severe Hypertriglyceridemia and Spontaneous Atherosclerosis: A Rodent Model Rescued From Neonatal Death. Metabolism. 2020 Jun 17;154296. doi:10.1016/j.metabol.2020.154296.
Current Research Grants
1. National Natural Science Foundation of Science (NSFC)：（2023/1 - 2026/12）
2. Beijing Natural Science Foundation of Science（2024/1 - 2026/12）
Patents Granted as First Inventor in the Last Five Years:
1. Application of Kif13b Gene in Treating Atherosclerosis. 2025-10-10, China, CN 119242788 B
2. Application of Kif13b Gene in Treating Abdominal Aortic Aneurysm. 2025-9-19, China, CN 119391853 B
3. Application of CBL Inhibitor NX1607 in Preparing Drugs for Treating Atherosclerosis. 2025-06-02, China, CN 119868356 A
4. Application of Scavenger Receptor Class A Type 3 or Reagents Increasing Its Expression in Preparing Products for Lowering Blood Glucose. 2024-08-27, China, CN 118161596B
5. Method for Constructing SCARA3 Gene Knockout Hamster Model. 2023-05-26, China, CN202210545169.X
6. Kit and Method for Constructing ABCA1 Gene Knockout Model. 2021-9-24, China, CN201811376682.0
7. Kit and Method for Constructing ApoC2 Gene Knockout Hamster Model. 2020-7-7, China, CN201811179674.7
8. System and Method for Constructing LCAT Gene Knockout Model. 2020-5-26, China, CN201810201435.0
9. A CONSTRUCTION METHOD OF APOC3 GENE NON-EXPRESSION HAMSTER MODEL. 2024-03-27, South Africa, C12N.202308300
10. CONSTRUCTION METHOD OF APOA5 GENE KNOCKOUT HAMSTER MODEL. 2024-03-22, Nigeria, CRP: 010781
11. A CONSTRUCTION METHOD OF IL-10 GENE NON-EXPRESSION HAMSTER MODEL. 2024-03-27, South Africa, C12N.202308299